Inhibition of cortactin and SIRT1 expression attenuates migration and invasion of prostate cancer DU145 cells

International Journal of Urology

Volumn 19, Issue 1, 2012, Pages 71-79

  Nakane, Keita ^a,b   Fujita, Yasunori ^b,d   Terazawa, Riyako ^b   Atsumi, Yuko ^b   Kato, Taku ^a,b   Nozawa, Yoshinori ^b,c   Deguchi, Takashi ^a   Ito, Masafumi ^b,d  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b GIFU INTERNATIONAL INSTITUTE OF BIOTECHNOLOGY   (Japan)

^c Tokai Women's Junior College   (Japan)

^d TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

Author keywords

Cortactin; DU145 cells; Invasion; Prostate cancer; Silent mating type information regulation2 homolog1

Indexed keywords

CORTACTIN; SIRTUIN 1; SMALL INTERFERING RNA;

ACETYLATION; ARTICLE; CANCER CELL; CELL INVASION; CELL MIGRATION; CELL STRAIN LNCAP; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOFLUORESCENCE MICROSCOPY; IN VIVO STUDY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; WESTERN BLOTTING;

ACETYLATION; CELL LINE, TUMOR; CELL MOVEMENT; CORTACTIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASM INVASIVENESS; PROSTATE; PROSTATIC NEOPLASMS; RNA, SMALL INTERFERING; SIRTUIN 1; UP-REGULATION;

EID: 84855187981     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2011.02888.x     Document Type: Article

References (32)

1. Wu H, Reynolds AB, Kanner SB, Vines RR, Parsons JT. Identification and characterization of a novel cytoskeleton-associated pp60src substrate. Mol. Cell. Biol. 1991; 11: 5113-24.
2. Weaver AM. Cortactin in tumor invasiveness. Cancer Lett. 2008; 265: 157-66.
3. Timpson P, Wilson AS, Lehrbach GM, Sutherland RL, Musgrove EA, Daly RJ. Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib. Cancer Res. 2007; 67: 9304-14.
4. Luo ML, Shen XM, Zhang Y etal. Amplification and overexpression of CTTN (EMS1) contribute to the metastasis of esophageal squamous cell carcinoma by promoting cell migration and anoikis resistance. Cancer Res. 2006; 66: 11690-9.
5. Li Y, Tondravi M, Liu J etal. Cortactin potentiates bone metastasis of breast cancer cells. Cancer Res. 2001; 61: 6906-11.
6. Tsai WC, Jin JS, Chang WK etal. Association of cortactin and fascin-1 expression in gastric adenocarcinoma: correlation with clinicopathological parameters. J. Histochem. Cytochem. 2007; 55: 955-62.
7. Yuan BZ, Zhou X, Zimonjic DB, Durkin ME, Popescu NC. Amplification and overexpression of the EMS 1 oncogene, a possible prognostic marker, in human hepatocellular carcinoma. J. Mol. Diagn. 2003; 5: 48-53.
8. Zhang LH, Tian B, Diao LR etal. Dominant expression of 85-kDa form of cortactin in colorectal cancer. J. Cancer Res. Clin. Oncol. 2006; 132: 113-20.
9. Zhang Y, Zhang M, Dong H etal. Deacetylation of cortactin by SIRT1 promotes cell migration. Oncogene 2009; 28: 445-60.
10. Michan S, Sinclair D. Sirtuins in mammals: insights into their biological function. Biochem. J. 2007; 404: 1-13.
11. Liu T, Liu PY, Marshall GM. The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res. 2009; 69: 1702-5.
12. Kuzmichev A, Margueron R, Vaquero A etal. Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc. Natl. Acad. Sci. U.S.A. 2005; 102: 1859-64.
13. Huffman DM, Grizzle WE, Bamman MM etal. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res. 2007; 67: 6612-18.
14. Byles V, Chmilewski LK, Wang J etal. Aberrant cytoplasm localization and protein stability of SIRT1 is regulated by PI3K/IGF-1R signaling in human cancer cells. Int. J. Biol. Sci. 2010; 6: 599-612.
15. Kojima K, Ohhashi R, Fujita Y etal. A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells. Biochem. Biophys. Res. Commun. 2008; 373: 423-8.
16. Fujita Y, Kojima K, Ohhashi R etal. MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression. J. Biol. Chem. 2010; 285: 19076-84.
17. Hida Y, Kubo Y, Murao K, Arase S. Strong expression of a longevity-related protein, SIRT1, in Bowen's disease. Arch. Dermatol. Res. 2007; 299: 103-6.
18. Yeung F, Hoberg JE, Ramsey CS etal. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 2004; 23: 2369-80.
19. Luo J, Nikolaev AY, Imai S etal. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001; 107: 137-48.
20. Tanno M, Sakamoto J, Miura T, Shimamoto K, Horio Y. Nucleocytoplasmic shuttling of the NAD+-dependent histone deacetylase SIRT1. J. Biol. Chem. 2006; 282: 6823-32.
21. Jung-Hynes B, Nihal M, Zhong W, Ahmad N. Role of sirtuin histone deacetylase SIRT1 in prostate cancer: a target for prostate cancer management via its inhibition? J. Biol. Chem. 2008; 284: 3823-32.
22. Eisenberger MA, Blumenstein BA, Crawford ED etal. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N. Engl. J. Med. 1998; 339: 1036-42.
23. Tannock IF, de Wit R, Berry WR etal. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004; 351: 1502-12.
24. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest. Urol. 1979; 17: 16-23.
25. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. Isolation of a human prostate carcinoma cell line (DU 145). Int. J. Cancer 1978; 21: 274-81.
26. Pulukuri SM, Gondi CS, Lakka SS etal. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J. Biol. Chem. 2005; 280: 36529-40.
27. Sainaghi PP, Castello L, Bergamasco L, Galletti M, Bellosta P, Avanzi GC. Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor. J. Cell. Physiol. 2005; 204: 36-44.
28. Ni Z, Lou W, Leman ES, Gao AC. Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells. Cancer Res. 2000; 60: 1225-8.
29. Uruno T, Liu J, Zhang P etal. Activation of Arp2/3 complex-mediated actin polymerization by cortactin. Nat. Cell Biol. 2001; 3: 259-66.
30. Clark ES, Weaver AM. A new role for cortactin in invadopodia: regulation of protease secretion. Eur. J. Cell Biol. 2008; 87: 581-90.
31. Artym VV, Zhang Y, Seillier-Moiseiwitsch F, Yamada KM, Mueller SC. Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia: defining the stages of invadopodia formation and function. Cancer Res. 2006; 66: 3034-43.
32. Clark ES, Whigham AS, Yarbrough WG, Weaver AM. Cortactin is an essential regulator of matrix metalloproteinase secretion and extracellular matrix degradation in invadopodia. Cancer Res. 2007; 67: 4227-35.